MétaCan
Menu
Back to cohort

P201 Bezafibrate as second line treatment in patients with primary biliary cholangitis: a real world experience

2021· article· en· W3122581691 on OpenAlexaboutno aff
Rebecca McCabe, Martin R. Prince, Shaun Greer, Harpreet Dhaliwal

Bibliographic record

Venuenot available
Typearticle
Languageen
FieldMedicine
TopicLiver Diseases and Immunity
Canadian institutionsnot available
Fundersnot available
KeywordsUrsodeoxycholic acidBezafibrateMedicineInternal medicineGastroenterologyAlkaline phosphatasePrimary biliary cirrhosisBile acid

Abstract

fetched live from OpenAlex

Introduction Failure to improve alkaline phosphatase (ALP) with treatment with Ursodeoxycholic acid (UDCA) is associated with reduced transplant-free survival in primary biliary cholangitis (PBC). Bezafibrate (BZ), as second line treatment, has been shown to be effective in improving ALP in patients with PBC in a recent randomised controlled trial1 but ‘real world’ data is limited. Aim and Method The aim of this study was to retrospectively assess the effectiveness of BZ as second line treatment in patients intolerant of, or non-responsive to UDCA in a single tertiary referral centre. ALP was recorded at six and twelve months of treatment and compared to baseline. Biochemical response was defined by the Toronto criteria of ALP less than 1.67 times the upper limit of normal. Results are expressed as median (range). Results 36 patients were identified as treated with BZ. Eight have been excluded as lost to follow-up (n=1) or had been taking BZ less than six months (n=7). Of the remaining 28 (5 UDCA intolerant, 23 UCDA incomplete response), 23 were female, median age was 54 (32–85) at the start of treatment and 11 patients (40%) had cirrhosis. Three (10.7%) patients stopped treatment due to intolerance (deteriorating renal function n=1; cramps n=1 and gastrointestinal symptoms n=1). The latter were both also intolerant to UDCA. In the remaining 25, ALP fell from 279 (125–782) to 154 (74 – 415) at six months, with 76% achieving biochemical response by Toronto criteria. 16 patients have completed 12 months of treatment, with 12 patients (75%) achieving biochemical response. ALP fell from 281 (125 – 720) to 138.5 (90–326) at 12 months. 7 (44%) patients normalised ALP. 20 patients were asked about pruritis before and after treatment. 6 patients (30%) reported no itch either before or after treatment, 2 (10%) reported no change in severity and 12 patients (60%) reported improvement in pruritis. Conclusion We have found that BZ is an effective second-line treatment, with 75% of those who tolerated it achieving biochemical response at 12 months. It was well tolerated and was also associated with improvement in pruritus in the majority of patients. Further research is required to assess the long-term outcome in these patients. Reference Corpechot C, et al. A Placebo-Controlled Trial of Bezafibrate in PBC. NEJM 2018;378;23:2171–81.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.004

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0010.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.012
GPT teacher head0.254
Teacher spread0.242 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2021
Admission routes1
Has abstractyes

Explore more

Same topicLiver Diseases and ImmunityFrench-language works237,207